We suggest a cutoff of 1.6 pg/mL as being useful prognostically in both BMPR2-positive and PAH without mutations (3-year survival in the whole cohort of 94.9% vs 70.1%; P = .0002). This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.